Objectives To investigate the role of tyrosine kinase Fyn in the development of osteoarthritis (OA) and the underlying mechanisms, and to define whether targeting Fyn could prevent OA in mice.
Methods Cartilage samples from normal and aged mice were analysed with proteome-wide screening. Fyn expression was examined with immunofluorescence in human and age-dependent or experimental mouse OA cartilage samples. Experimental OA in Fyn-knockout mice was induced by destabilisation of the medial meniscus. Primary cultured mouse chondrocytes were treated with proinflammatory cytokine interleukin-1β. The inhibitor of Src kinase family, AZD0530 (saracatinib), and inhibitor of Fyn, PP1, were used to treat experimental OA in mice.
Results Fyn expression was markedly upregulated in human OA cartilage and in cartilage from aged mice and those with post-traumatic OA. Fyn accumulates in articular chondrocytes and interacts directly with and phosphorylates β-catenin at Tyr142, which stabilises β-catenin and promotes its nuclear translocation. The deletion of Fyn effectively delayed the development of post-traumatic and age-dependent OA in mice. Fyn inhibitors AZD0530 and PP1 significantly attenuated OA progression by blocking the β-catenin pathway and reducing the levels of extracellular matrix catabolic enzymes in the articular cartilage.
Conclusions Fyn accumulates and activates β-catenin signalling in chondrocytes, accelerating the degradation of the articular cartilage and OA development. Targeting Fyn is a novel and potentially therapeutic approach to the treatment of OA.
- knee osteoarthritis
Statistics from Altmetric.com
Handling editor Josef S Smolen
Contributors KL: study design, data acquisition, data analysis, wrote the manuscript, DMM experiments. YueZ, YuwZ, WJ and JS: data analysis, discussion of results, confocal imaging and analysis. SX, QS and DC: data acquisition, histochemistry and western blotting analysis. BH, AL and ML: data acquisition. JS and YJ: statistical analyses. XB: study design, manuscript correction.
Funding This work was supported by grants from the National Natural Science Foundation of China (nos. 81625015, 81530070, 31529002, 81772406).
Competing interests None declared.
Patient consent Obtained.
Ethics approval All animal experiments were approved by the Southern Medical University Animal Care and Use Committee (Guangzhou, China).
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.